Compare VIV & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VIV | ROIV |
|---|---|---|
| Founded | 1973 | 2014 |
| Country | Brazil | United Kingdom |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.1B | 23.2B |
| IPO Year | 1998 | 2021 |
| Metric | VIV | ROIV |
|---|---|---|
| Price | $13.12 | $35.31 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | $14.80 | ★ $28.94 |
| AVG Volume (30 Days) | 1.0M | ★ 5.7M |
| Earning Date | 05-12-2026 | 05-28-2026 |
| Dividend Yield | ★ 2.47% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,260,000.00 |
| Revenue This Year | $9.22 | N/A |
| Revenue Next Year | $5.52 | $744.61 |
| P/E Ratio | $22.12 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.81 | $10.71 |
| 52 Week High | $17.26 | $35.90 |
| Indicator | VIV | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 43.51 | 76.45 |
| Support Level | $12.61 | $27.15 |
| Resistance Level | $13.29 | N/A |
| Average True Range (ATR) | 0.28 | 1.18 |
| MACD | 0.11 | 0.50 |
| Stochastic Oscillator | 51.94 | 90.90 |
Telefonica Brasil, known as Vivo, is the largest wireless carrier in Brazil with 103 million customers, which is equal to about 38% market share. The firm is strongest in the postpaid business, where it has 72 million customers, or about 40% share of this market. Wireless services and equipment contribute about 70% of total revenue. Vivo is the incumbent fixed-line telephone operator in Sao Paulo state and also owns an extensive fiber network across the country. The firm provides internet access to 8 million households on this network. The firm also sells pay-TV and phone services to its fixed-line customers. Finally, corporate data and IT services, including cloud computing support, contribute about 10% of total revenue.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.